{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-208858","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.227290+00:00","generated_at":"2026-06-24T06:28:46.328270+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Acumen presents ADDL assay method to standardize AßO testing for Alzheimer's therapeutics","bullets":["Presented poster at AAIC 2022 on using ADDLs as synthetic AßO reference standard for bioanalytical assays.","ADDL model addresses low concentration, instability, and heterogeneity of sAßOs in Alzheimer's brain.","ACU193 Phase 1 trial ongoing; poster supports understanding of oligomer role in Alzheimer's disease.","Panel of sAßO-targeting antibodies showed variable immunoreactivity with ADDLs; 20C2 selective over monomers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-208858","json":"https://secwatch.observer/filing/0001193125-22-208858.json","markdown":"https://secwatch.observer/filing/0001193125-22-208858.md","text":"https://secwatch.observer/filing/0001193125-22-208858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522208858/0001193125-22-208858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522208858/d690801d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:28:46.328270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}